Abstract 8452: Beta-Blocker Therapy and Atrioventricular Conduction Outcomes in Heart Failure with Reduced Ejection Fraction and Fascicular Block
Abstract
Background: Beta-blockers are a cornerstone of guideline-directed medical therapy for heart failure with reduced ejection fraction (HFrEF). However, their safety in patients with pre-existing fascicular or bundle-branch block remains uncertain because of potential adverse effects on atrioventricular (AV) conduction. Hypothesis: Among patients with HFrEF and baseline fascicular or bundle-branch block, beta-blocker therapy is associated with increased risk of clinically significant AV conduction disturbances. Methods: We performed a retrospective cohort study using the TriNetX US Collaborative Network. Adults with HFrEF and documented fascicular or bundle-branch block were identified and stratified by beta-blocker exposure. Patients receiving metoprolol, carvedilol, or bisoprolol were compared with patients without beta-blocker exposure. Propensity score matching was performed using 35 demographic, clinical, laboratory, and medication covariates, yielding 29,572 patients per group. Primary outcomes were complete AV block and pacemaker implantation. Secondary outcomes included major adverse cardiovascular events (MACE), first-degree AV block, and second-degree AV block. Time-to-event analyses were performed using Kaplan-Meier methods, with Cox proportional hazards and Fine-Gray competing-risk models as sensitivity analyses. Results: Beta-blocker use was associated with a 45% increased incidence of complete AV block (HR 1.450 [1.293, 1.627]; p < 0.0001) and 44% increased incidence of pacemaker implantation (HR 1.436 [1.342, 1.537]; p < 0.0001), with no difference in MACE (HR 0.996 [0.958, 1.035]; p = 0.840). Similarly, increased risks were observed for second-degree AV block (HR 1.392 [1.157, 1.676]; p<0.0001) and first-degree AV block (HR 1.658 [1.508, 1.823]; p<0.0001). Competing-risk analyses confirmed increased cumulative incidence of complete AV block (sHR 1.514 [1.445, 1.587]; p<0.0001) and pacemaker implantation (sHR 1.534 [1.471, 1.601]; p<0.0001). In agent-specific analyses, metoprolol demonstrated the highest risk of complete AV block (HR 1.550 [1.373, 1.749]; p<0.0001), whereas carvedilol was associated with the lowest risk (HR 1.228 [1.079, 1.398]; p=0.0019). Conclusions: In patients with HFrEF and underlying fascicular or bundle-branch block, beta-blocker therapy was associated with substantially increased risk of AV conduction disturbances and pacemaker implantation without a reduction in major cardiovascular events. These findings suggest that baseline conduction system disease may modify the risk-benefit profile of beta-blocker therapy and warrant further prospective evaluation.